Vigorous shaking can denature the peptide and introduce air
Severe gastrointestinal symptoms may lead to dehydration and acute kidney injury in some patients
Approval 2022) Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes (March 01, 2023) Tirzepatide On Ingestive Behavior In Adults With Overweight Or Obesity: A Randomized 6-Week Phase 1 Trial (June 24, 2025) Mounjaro (Tirzepatide) Injection, For Subcutaneous Use (Initial U.S
Results vary depending on several factors, including: starting body weight dosage consistency nutrition habits sleep activity level underlying metabolic health Some people notice gradual, steady fat loss, while others experience more dramatic changes after dosage increases
For patients, the practical difference is visibility